Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Reid

Showing results (71-80 of 150) with videos related to

Pageof 15
Sort By:
Calcified Tissue International|November 22, 2008
Increase in vertebral fracture risk in postmenopausal women using omeprazoleChristian Roux, Karine Briot, Laure Gossec, et al.
Journal of the American Dental Association (1939)|November 2, 2010
The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials programJohn T Grbic, Dennis M Black, Kenneth W Lyles, et al.
Plant Physiology and Biochemistry : PPB|July 20, 2012
Ethylene involvement in silique and seed development of canola, Brassica napus LLinda J Walton, Leonid V Kurepin, Edward C Yeung, et al.
Bone|November 5, 2010
Fluvastatin does not prevent the acute-phase response to intravenous zoledronic acid in post-menopausal womenKeith Thompson, Fran Keech, David J McLernon, et al.
The American Journal of Clinical Nutrition|December 20, 2003
Lower estimates of net endogenous non-carbonic acid production are positively associated with indexes of bone health in premenopausal and perimenopausal womenSusan A New, Helen M MacDonald, Marion K Campbell, et al.
Bone|February 22, 2012
Effects of 3 years of lasofoxifene treatment on bone turnover markers in women with postmenopausal osteoporosisRichard Eastell, David M Reid, Slobodan Vukicevic, et al.
Cancer Treatment Reviews|June 3, 2008
Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert GroupDavid M Reid, Julie Doughty, Richard Eastell, et al.
Annals of Epidemiology|June 26, 2018
A high anticholinergic burden is associated with a history of falls in the previous year in middle-aged women: findings from the Aberdeen Prospective Osteoporosis Screening StudyAndrew D Ablett, Adrian D Wood, Rebecca Barr, et al.
The British Journal of Nutrition|June 23, 2009
Changes in vitamin biomarkers during a 2-year intervention trial involving increased fruit and vegetable consumption by free-living volunteersHelen M Macdonald, Antonia C Hardcastle, Garry G Duthie, et al.
Therapeutic Advances in Drug Safety|June 18, 2020
Anticholinergic burden in middle-aged women and recurrent falls in later life: findings from the Aberdeen prospective osteoporosis screening study (APOSS)Samuel R Neal, Adrian D Wood, Andrew D Ablett, et al.
Pageof 15

Showing results (71-80 of 150) with videos related to

Sort By:
Pageof 15
Calcified Tissue International|November 22, 2008
Increase in vertebral fracture risk in postmenopausal women using omeprazoleChristian Roux, Karine Briot, Laure Gossec, et al.
Journal of the American Dental Association (1939)|November 2, 2010
The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials programJohn T Grbic, Dennis M Black, Kenneth W Lyles, et al.
Plant Physiology and Biochemistry : PPB|July 20, 2012
Ethylene involvement in silique and seed development of canola, Brassica napus LLinda J Walton, Leonid V Kurepin, Edward C Yeung, et al.
Bone|November 5, 2010
Fluvastatin does not prevent the acute-phase response to intravenous zoledronic acid in post-menopausal womenKeith Thompson, Fran Keech, David J McLernon, et al.
The American Journal of Clinical Nutrition|December 20, 2003
Lower estimates of net endogenous non-carbonic acid production are positively associated with indexes of bone health in premenopausal and perimenopausal womenSusan A New, Helen M MacDonald, Marion K Campbell, et al.
Bone|February 22, 2012
Effects of 3 years of lasofoxifene treatment on bone turnover markers in women with postmenopausal osteoporosisRichard Eastell, David M Reid, Slobodan Vukicevic, et al.
Cancer Treatment Reviews|June 3, 2008
Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert GroupDavid M Reid, Julie Doughty, Richard Eastell, et al.
Annals of Epidemiology|June 26, 2018
A high anticholinergic burden is associated with a history of falls in the previous year in middle-aged women: findings from the Aberdeen Prospective Osteoporosis Screening StudyAndrew D Ablett, Adrian D Wood, Rebecca Barr, et al.
The British Journal of Nutrition|June 23, 2009
Changes in vitamin biomarkers during a 2-year intervention trial involving increased fruit and vegetable consumption by free-living volunteersHelen M Macdonald, Antonia C Hardcastle, Garry G Duthie, et al.
Therapeutic Advances in Drug Safety|June 18, 2020
Anticholinergic burden in middle-aged women and recurrent falls in later life: findings from the Aberdeen prospective osteoporosis screening study (APOSS)Samuel R Neal, Adrian D Wood, Andrew D Ablett, et al.
Pageof 15